



September 27, 2013

The Honorable Tom Harkin
Chairman
Committee on Health, Education, Labor and Pensions
U.S. Senate
Washington, DC 20510

The Honorable Fred Upton
Chairman
Committee on Energy and Commerce
U.S. House of Representatives
Washington, DC 20510

The Honorable Lamar Alexander
Ranking Member
Committee on Health, Education, Labor and Pensions
U.S. Senate
Washington, DC 20510

The Honorable Henry Waxman
Ranking Member
Committee on Energy and Commerce
U.S. House of Representatives
Washington, DC 20510

Dear Chairman Harkin, Ranking Member Alexander, Chairman Upton and Ranking Member Waxman:

On behalf of the Biotechnology Industry Organization (BIO) I am writing to express our support for the traceability provisions in the Drug Quality and Security Act, and we urge this legislation be enacted. We believe this bipartisan, bicameral consensus breaks the logjam on the major issues that have held up drug distribution security legislation for the past several years.

BIO members are committed to further strengthening the biopharmaceutical supply chain to protect patients from potentially counterfeit or adulterated drugs. To that end, we support the establishment of strong, uniform, scalable national standards for drug serialization and tracing systems contained in this legislation, rather than relying on the emerging patchwork of individual state mandates. We greatly appreciate your tireless efforts, along with the other members of the Committees, to craft this careful compromise.

The success of a national traceability system depends on the full engagement and participation of all trading partners. We will continue to work constructively with the Congress, FDA and our supply chain partners as we build a national system to prevent counterfeit medicines from reaching patients.

Sincerely,

A handwritten signature in black ink that reads "Jim Greenwood". The signature is written in a cursive, flowing style.

James C. Greenwood
President and CEO